Symbol | Exchange | Currency |
|---|
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about...
Sharecast - At the close, the Dow Jones Industrial Average was up 3.7% at 33,715.37, as the S&P 500 added 5.54% to 3,956.37 and the Nasdaq Composite was 7.35% firmer at...
• FTSE 100 up, but off best levels • US stocks seen higher, more key results due • IMI (LON:IMI) results please analysts FTSE 100 held in positive territory in early...
After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine...
Equal-weighted exchange-traded funds (ETFs) invest equal amounts in businesses irrespective of their market capitalizations. Conversely, a cap-weighted index, allows companies with...
For a company that has been at the forefront of the fight against Covid-19, the AstraZeneca PLC (LON:AZN) (NASDAQ:AZN) share price performance has been very underwhelming. Stocks...
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) which is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 which is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which is in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. It serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has a collaboration and license agreement with Neurimmune AG, Dicerna, Merck, and Zealand Pharma. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Zürich, Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 116.00 | 116.00 | 116.00 | 0.00 | 0.00% | 0.00 | London | |||
| 3.50 | 3.50 | 3.50 | -0.30 | -7.69% | 520.00K | London | |||
| 1,133.00 | 1,150.00 | 1,124.00 | -16.00 | -1.39% | 45.16K | London | |||
| 40.00 | 40.00 | 40.00 | 0.00 | 0.00% | 0.00 | London | |||
| 0.40 | 0.45 | 0.40 | -0.050 | -11.11% | 29.26K | London | |||
| 339.00 | 340.00 | 338.00 | 0.00 | 0.00% | 0.00 | London | |||
| 677.40 | 688.00 | 675.60 | -14.40 | -2.08% | 84.82K | London | |||
| 198.25 | 198.25 | 198.25 | -2.75 | -1.37% | 8.80K | London | |||
| 64.55 | 64.55 | 64.55 | -0.45 | -0.69% | 58.00 | London | |||
| 14.05 | 14.05 | 14.05 | -2.45 | -14.85% | 262.00 | London | |||
| 11.50 | 11.50 | 11.50 | 0.00 | 0.00% | 0.00 | London | |||
| 163.00 | 165.00 | 162.30 | +1.00 | +0.62% | 18.04K | London | |||
| 354.00 | 355.00 | 353.00 | +2.00 | +0.57% | 18.70K | London | |||
| 105.75 | 106.40 | 105.00 | +1.00 | +0.95% | 486.75K | London | |||
| 0.09 | 0.12 | 0.06 | 0.00 | 0.00% | 0.00 | London |